Literature DB >> 21105218

Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets.

Nunzio Pomara1, John J Sidtis.   

Abstract

The monoamine hypothesis ascribes an important role to the under activity of brain monoamines such as 5-HT, noradrenaline and dopamine to the pathophysiology of depression. This view emerged more than 50 years ago and has guided development of most medications currently used for the treatment of this disorder. However, large numbers of depressed individuals treated with currently available antidepressant agents, or even with various combinations, do not respond. Residual symptoms, relapses and recurrences are common while receiving adequate doses of these medications. In a recent issue of the BJP, Colaianna et al.describe results suggesting that a new neurobiological mechanism with treatment implications should be considered for the development of depression in humans, namely, elevations in potentially neurotoxic brain amyloid-ß peptides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105218      PMCID: PMC2992893          DOI: 10.1111/j.1476-5381.2010.00948.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Serum amyloid beta protein in young and elderly depression: a pilot study.

Authors:  Yohei Kita; Hajime Baba; Hitoshi Maeshima; Yoshiyuki Nakano; Toshihito Suzuki; Heii Arai
Journal:  Psychogeriatrics       Date:  2009-12       Impact factor: 2.440

2.  Deep brain stimulation for treatment-resistant depression.

Authors:  Helen S Mayberg; Andres M Lozano; Valerie Voon; Heather E McNeely; David Seminowicz; Clement Hamani; Jason M Schwalb; Sidney H Kennedy
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

3.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.

Authors:  John R Cirrito; Kelvin A Yamada; Mary Beth Finn; Robert S Sloviter; Kelly R Bales; Patrick C May; Darryle D Schoepp; Steven M Paul; Steven Mennerick; David M Holtzman
Journal:  Neuron       Date:  2005-12-22       Impact factor: 17.173

4.  Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?

Authors:  M Colaianna; P Tucci; M Zotti; M G Morgese; S Schiavone; S Govoni; V Cuomo; L Trabace
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

5.  Is there a CSF biomarker profile related to depression in elderly women?

Authors:  Pia Gudmundsson; Ingmar Skoog; Margda Waern; Kaj Blennow; Henrik Zetterberg; Lars Rosengren; Deborah Gustafson
Journal:  Psychiatry Res       Date:  2010-02-04       Impact factor: 3.222

6.  Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Authors:  Nunzio Pomara; P Murali Doraiswamy; Lisa M Willoughby; Amy E Roth; Benoit H Mulsant; John J Sidtis; Pankaj D Mehta; Charles F Reynolds; Bruce G Pollock
Journal:  Neurochem Res       Date:  2006-04-01       Impact factor: 3.996

7.  Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque.

Authors:  J Jacob Kulstad; Pamela J McMillan; James B Leverenz; David G Cook; Pattie S Green; Elaine R Peskind; Charles W Wilkinson; Wesley Farris; Pankaj D Mehta; Suzanne Craft
Journal:  J Neuropathol Exp Neurol       Date:  2005-02       Impact factor: 3.685

8.  Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.

Authors:  Jae-Eun Kang; Miranda M Lim; Randall J Bateman; James J Lee; Liam P Smyth; John R Cirrito; Nobuhiro Fujiki; Seiji Nishino; David M Holtzman
Journal:  Science       Date:  2009-09-24       Impact factor: 47.728

9.  The relationship between cerebrospinal fluid biomarkers and depression in elderly women.

Authors:  Pia Gudmundsson; Ingmar Skoog; Margda Waern; Kaj Blennow; Sigurdur Pálsson; Lars Rosengren; Deborah Gustafson
Journal:  Am J Geriatr Psychiatry       Date:  2007-10       Impact factor: 4.105

10.  Effects of beta-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat.

Authors:  A Gonzalo-Ruiz; I González; J M Sanz-Anquela
Journal:  J Chem Neuroanat       Date:  2003-11       Impact factor: 3.052

View more
  6 in total

1.  Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.

Authors:  Wei Qiao Qiu; Haihao Zhu; Michael Dean; Zhiheng Liu; Linh Vu; Guanguang Fan; Huajie Li; Mkaya Mwamburi; David C Steffens; Rhoda Au
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-06       Impact factor: 3.485

Review 2.  Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?

Authors:  Nahla Mahgoub; George S Alexopoulos
Journal:  Am J Geriatr Psychiatry       Date:  2016-01-14       Impact factor: 4.105

Review 3.  Maternal Malnutrition in the Etiopathogenesis of Psychiatric Diseases: Role of Polyunsaturated Fatty Acids.

Authors:  Maria Grazia Morgese; Luigia Trabace
Journal:  Brain Sci       Date:  2016-07-27

4.  Mechanism Underlying Acupuncture-Ameliorated Depressive Behaviors by Enhancing Glial Glutamate Transporter in Chronic Unpredictable Mild Stress (CUMS) Rats.

Authors:  Ding Luo; Rui Ma; Yanan Wu; Xuechun Zhang; Yue Liu; Lin Wang; Wenbin Fu
Journal:  Med Sci Monit       Date:  2017-06-23

5.  Lifelong Nutritional Omega-3 Deficiency Evokes Depressive-Like State Through Soluble Beta Amyloid.

Authors:  Maria Grazia Morgese; Paolo Tucci; Emanuela Mhillaj; Maria Bove; Stefania Schiavone; Luigia Trabace; Vincenzo Cuomo
Journal:  Mol Neurobiol       Date:  2016-02-29       Impact factor: 5.590

6.  Precision Medicine in Alzheimer's Disease: Investigating Comorbid Common Biological Substrates in the Rat Model of Amyloid Beta-Induced Toxicity.

Authors:  Maria Grazia Morgese; Maria Bove; Lorenzo Di Cesare Mannelli; Stefania Schiavone; Anna Laura Colia; Stefania Dimonte; Emanuela Mhillaj; Vladyslav Sikora; Paolo Tucci; Carla Ghelardini; Luigia Trabace
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.